Recent studies have suggested that PUVA treatment may help reduce itching and clinical severity scores in AD patients by regulating epidermal nerve density and the expression of specific axonal molecules like semaphorin 3A (Sema3A) and nerve growth factor (NGF). This evidence concerns the gene NGF and Alzheimer disease.